ArticleQuantitative imaging in medicine and surgery2026
Safety and efficacy of ultrasound-guided microwave ablation in patients with primary hyperparathyroidism: a single-center retrospective study.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ultrasound (US)-guided microwave ablation (MWA) for primary hyperparathyroidism (PHPT) is a relatively novel minimally invasive treatment. However, definitive evidence for the efficacy of thermal ablation in treating PHPT is not well characterized. This work aimed to evaluate the effectiveness and safety of US-guided MWA in patients with PHPT. Methods: This retrospective study analyzed the data of patients diagnosed with PHPT who underwent US-guided MWA at Peking University First Hospital between October 2020 and October 2024. Serum levels of parathyroid hormone (PTH), calcium, and phosphate were measured preoperatively and at 3, 6, and 12 hours post-MWA to assess immediate biochemical changes. Long-term therapeutic outcomes were evaluated by monitoring the volume of ablation areas and serum PTH, calcium, and phosphate levels at 1, 3, 6, and 12 months post-MWA or at the last follow-up. Results: A total of 30 clinical records were reviewed, of which 25 (15 female and 10 male; mean age: 60.04±17.38 years) met the inclusion criteria and were included in the final analysis. No clinically significant complications were observed during or following the MWA procedure. Serum PTH levels showed a significant reduction at 3, 6, and 12 hours post-MWA compared to baseline. Serum calcium levels began to decrease significantly at 3 hours post-MWA, whereas serum phosphate levels showed no significant changes within the first 12 hours. Serum PTH levels were significantly lower at the last follow-up (mean duration: 7.48 ± 4.8 months) compared to baseline (P=0.002). Serum calcium levels were significantly lower at 1 month and at the last follow-up (P=0.0021) compared to baseline. At the last follow-up, the volume reduction ratio (VRR) of the ablated masses was 71.5%±29%. Conclusions: Our study provides evidence that US-guided MWA is safe and effective for managing PHPT adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.